Biome Australia Ltd (ASX: BIO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Biome Australia Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$101.29 million
P/E Ratio
450.00
Dividend Yield
0.00%
Shares Outstanding
222.61 million
Earnings per share
0.001
Dividend per share
N/A
Year To Date Return
7.14%
Earnings Yield
0.22%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Biome Australia Ltd (ASX: BIO)
Latest News
Healthcare Shares
This probiotics company has just struck a distribution deal, sending its shares sharply higher
Small Cap Shares
Are these ASX small-cap stocks about to double?
Small Cap Shares
This ASX small-cap stock just jumped 10%. Here's why
Small Cap Shares
The ASX small-cap stock that could double in value in 2026
Healthcare Shares
Broker lists one ASX healthcare stock as a buy and one a sell
Small Cap Shares
Why these small cap ASX shares could deliver big returns in 2025
Small Cap Shares
Guess which small cap ASX stock could rise 45%
IPOs
The Biome Australia (ASX: BIO) share price just flopped on IPO
BIO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Biome Australia Ltd
Biome Australia Ltd licences, develops, and markets evidence-based, complementary medicines, including nutraceuticals vitamins and weight management products and live biotherapeutics. The company has one operating segment: researching, developing, manufacturing and distributing evidence-based products linking the gut and human health. Domestically it caters to Australia and In international markets, the Group distributes and markets its Activated Probiotics range in the United Kingdom and New Zealand through independent health practitioners.
BIO Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | $0.45 | $-0.01 | -2.17% | 396,606 | $0.46 | $0.47 | $0.42 |
| 05 Feb 2026 | $0.46 | $-0.01 | -2.11% | 209,918 | $0.48 | $0.48 | $0.46 |
| 04 Feb 2026 | $0.48 | $-0.01 | -2.08% | 86,955 | $0.49 | $0.49 | $0.48 |
| 03 Feb 2026 | $0.48 | $0.00 | 0.00% | 237,494 | $0.49 | $0.49 | $0.48 |
| 02 Feb 2026 | $0.48 | $0.03 | 6.67% | 694,657 | $0.45 | $0.49 | $0.45 |
| 30 Jan 2026 | $0.45 | $-0.01 | -2.20% | 157,767 | $0.46 | $0.46 | $0.44 |
| 29 Jan 2026 | $0.46 | $-0.01 | -2.15% | 339,708 | $0.47 | $0.47 | $0.46 |
| 28 Jan 2026 | $0.47 | $0.02 | 4.44% | 321,270 | $0.45 | $0.48 | $0.45 |
| 27 Jan 2026 | $0.45 | $0.01 | 2.27% | 783,877 | $0.45 | $0.46 | $0.43 |
| 23 Jan 2026 | $0.44 | $-0.01 | -2.25% | 106,951 | $0.45 | $0.45 | $0.43 |
| 22 Jan 2026 | $0.45 | $0.00 | 0.00% | 133,777 | $0.45 | $0.45 | $0.44 |
| 21 Jan 2026 | $0.45 | $-0.02 | -4.35% | 475,908 | $0.45 | $0.46 | $0.44 |
| 20 Jan 2026 | $0.46 | $0.01 | 2.20% | 125,300 | $0.46 | $0.46 | $0.46 |
| 19 Jan 2026 | $0.46 | $-0.02 | -4.21% | 320,100 | $0.47 | $0.47 | $0.45 |
| 16 Jan 2026 | $0.48 | $0.01 | 2.13% | 503,021 | $0.47 | $0.48 | $0.46 |
| 15 Jan 2026 | $0.47 | $0.03 | 6.90% | 759,516 | $0.43 | $0.47 | $0.43 |
| 14 Jan 2026 | $0.44 | $0.00 | 0.00% | 309,930 | $0.43 | $0.44 | $0.43 |
| 13 Jan 2026 | $0.44 | $0.02 | 4.76% | 511,168 | $0.42 | $0.44 | $0.41 |
| 12 Jan 2026 | $0.42 | $0.01 | 2.47% | 100,717 | $0.41 | $0.42 | $0.40 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Dec 2025 | Geoffrey Sam | Issued | 2,000,000 | $860,000 |
Issue of securities. Nil cash consideration, Estimated valuation - $803,640
|
| 26 Nov 2025 | Blair Norfolk | Buy | 50,000 | $20,279 |
On-market trade.
|
| 07 Apr 2025 | Geoffrey Sam | Buy | 54,050 | $24,985 |
On-market trade.
|
| 28 Feb 2025 | Geoffrey Sam | Buy | 43,240 | $24,980 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Dominique Gayle Fisher | Non-Executive Director | Aug 2021 |
Ms Fisher couples her experience in tech driven businesses with a focus on risk mitigation and financial management which has led to her working in across a range of sectors in both executive and non-executive roles. Dominique has a Non Executive career, having served on ASX listed companies, IAG, Circadian Technologies/ Opthea, Pacific Brands and Trimantium GrowthOps (2 as Chair) including two IPOs (IAG and TGO); private companies including NRMA, LaunchVic and SkyTechnologies. Dominique has Audit, Remuneration and Risk Committee experience of listed and unlisted companies. Dominique has also served on various government and private advisory boards at both state and federal for both major political parties, Geoscape Australia and government agencies including the Sydney Opera House, Australia Post and the Australian Council for the Arts.
|
| Mr Geoffrey Joseph Sam | Non-Executive Director | Nov 2024 |
Mr Sam, building from his background in hospital executive leadership, he co-founded Healthecare Australia Pty Ltd in 2005. Healthecare Australia Pty Ltd is a privately owned healthcare company comprising a portfolio of 17 private hospitals and employing nearly 5,000 healthcare professionals nationwide. Geoff currently serves as a Non-Executive Director of IDT Ltd, Change Financial Ltd and EarlyPay Ltd. His past board positions include ParagonCare Ltd, Money 3 Ltd, Hutchinsons Childcare Services Ltd and Nova Health Ltd. With decades of executive and board-level experience in healthcare. He is chair of Risk Committee.
|
| Mr Blair Vega Norfolk | Chief Executive OfficerManaging Director | Jul 2018 |
Mr Norfolk has over 14 years of global pharmaceutical and nutraceutical industry experience as management and executive. Since founding the business, Blair has recruited the people, secured funding, products and IP and managed relationships. Blair has relationships in media, pharmacy, research and manufacturing. Blair has a public profile as a health advocate and speaks at conferences and panels from mental health to general wellbeing.
|
| Mr George Lazarou | Company Secretary |
-
|
|
| Douglas Chee Yong Loh | Chief financial officer |
-
|
|
| George Lazarou | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Ocean and Remi Pty Ltd <Cambria Partners A/C> | 18,209,955 | 8.25% |
| Raymond Demaio Pty Ltd <Raymond Demaio Family A/C> | 9,592,000 | 4.35% |
| HSBC Custody Nominees (Australia) Limited | 9,496,622 | 4.30% |
| Emmanuel Investment Holdings Pty Ltd <Loh Family A/C> | 6,102,010 | 2.77% |
| DC Retirement Nominees Pty Ltd <DC Family Trust A/C> | 4,523,728 | 2.05% |
| Burrangong Pty Ltd <Sam Family Settlement A/C> | 3,797,101 | 1.72% |
| Evergem Pty Ltd <The Evergem Unit A/C> | 3,420,000 | 1.55% |
| COB Pty Ltd | 3,380,000 | 1.53% |
| J P Morgan Nominees Australia Pty Limited | 3,039,320 | 1.38% |
| COB Pty Ltd i | 3,015,546 | 1.37% |
| Astro Superannuation Holdings Pty Ltd <Emmanuel Super Fund A/C> | 2,865,787 | 1.30% |
| Mr Yuk Chung Edward Chiu | 2,769,565 | 1.26% |
| Mr Paul James Madden | 2,671,848 | 1.21% |
| Mr Joshua Oliver Stanford Harris | 2,483,466 | 1.13% |
| See Breeze Consulting Pty Ltd | 2,418,349 | 1.10% |
| Carlisle and Co Pty Ltd <Wattle Superfund A/C> | 2,300,000 | 1.04% |
| Mr John William Bronger | 2,140,579 | 0.97% |
| Netwealth Investments Limited <Wrap Services A/C> | 2,055,366 | 0.93% |
| Qintet Pharma Partners Pty Ltd | 2,000,000 | 0.91% |
| Mrs Aini Loh | 1,636,883 | 0.74% |
